Products Categories
| CAS No.: | 863127-77-9 |
|---|---|
| Name: | Dasatinib monohydrate |
| Article Data: | 6 |
| Molecular Structure: | |
|
|
|
| Formula: | C22H26Cl N7O2S. H2O |
| Molecular Weight: | 506.028 |
| Synonyms: | 5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-,monohydrate (9CI);BMS 35482503;Dasatinib hydrate;Dasatinib;5-Thiazolecarboxamide,N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-,hydrate (1:1); |
| EINECS: | 638-874-6 |
| Density: | 1.408 g/cm3 |
| Melting Point: | 97-99°C(lit.) |
| Hazard Symbols: |
 C, Xi
|
| Risk Codes: | R34; R36/37/38 |
| PSA: | 143.98000 |
| LogP: | 3.39810 |
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
- 926293-55-26-Bromo-2-methylpyridine-3-carboxaldehyde
- 911112-05-55-Iodo-3-(trifluoromethyl)-2-pyridinamine
- 886364-50-71-(5-Bromo-2-pyridinyl)-2,2,2-trifluoroethanone
- 302962-49-8
dasatanib
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| With ethanol; water at 80℃; for 2h; Large scale; | 96.44% |
| With water In ethanol at 75 - 80℃; | |
| With water In ethanol at 0 - 80℃; for 5h; | |
| With water In methanol Solvent; Heating; | 21 g |
- 910297-51-7
N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-(piperazin-1-yl)pyrimidin 4-yl)amino)thiazole-5-carboxamide
- 540-51-2
2-bromoethanol
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| With caesium carbonate; potassium iodide In acetonitrile for 6h; Temperature; Solvent; Reagent/catalyst; Reflux; | 93% |
- 103-76-4
1-(2-hydroxyethyl)piperazine
- 302964-08-5
2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| Stage #1: 1-(2-hydroxyethyl)piperazine; 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide With N-ethyl-N,N-diisopropylamine In butan-1-ol at 118℃; for 4.5h; Stage #2: With water In ethanol | 83.2% |
| Stage #1: 1-(2-hydroxyethyl)piperazine; 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 100℃; for 2.5h; Stage #2: With water In N,N-dimethyl-formamide at 20 - 100℃; for 2h; |
- 302964-24-5
2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 4 steps 1.1: sodium t-butanolate / tetrahydrofuran / 10 - 20 °C 1.2: 2 h / 0 - 5 °C / pH 2 - 3 2.1: N-ethyl-N,N-diisopropylamine / pentan-1-ol / 8 h / Reflux 3.1: hydrogenchloride / water / 3 h / 55 - 60 °C 4.1: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme | |
| Multi-step reaction with 4 steps 1.1: sodium t-butanolate / tetrahydrofuran / 10 - 20 °C 1.2: 2 h / 0 - 5 °C / pH 2 - 3 2.1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 5 h / 80 - 85 °C 3.1: sulfuric acid / methanol / 5 h / 5 - 65 °C 4.1: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme |
- 302964-06-3
[5-(2-chloro-6-methylphenylcarbamoyl)thiazol-2-yl]-carbamic acid tert-butyl ester
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 5 steps 1.1: trifluoroacetic acid / 2 h / 25 - 30 °C 2.1: sodium t-butanolate / tetrahydrofuran / 10 - 20 °C 2.2: 2 h / 0 - 5 °C / pH 2 - 3 3.1: N-ethyl-N,N-diisopropylamine / pentan-1-ol / 8 h / Reflux 4.1: hydrogenchloride / water / 3 h / 55 - 60 °C 5.1: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme | |
| Multi-step reaction with 5 steps 1.1: trifluoroacetic acid / 2 h / 25 - 30 °C 2.1: sodium t-butanolate / tetrahydrofuran / 10 - 20 °C 2.2: 2 h / 0 - 5 °C / pH 2 - 3 3.1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 5 h / 80 - 85 °C 4.1: sulfuric acid / methanol / 5 h / 5 - 65 °C 5.1: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme |
- 302964-08-5
2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
- 863127-77-9
dasatinib monohydrate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 5 h / 80 - 85 °C 2: sulfuric acid / methanol / 5 h / 5 - 65 °C 3: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme | |
| Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine / pentan-1-ol / 8 h / Reflux 2: hydrogenchloride / water / 3 h / 55 - 60 °C 3: potassium iodide; caesium carbonate / acetonitrile / 6 h / Reflux View Scheme |
- 863127-77-9
dasatinib monohydrate
- 302962-49-8
dasatanib
| Conditions | Yield |
|---|---|
| In propan-1-ol; water at 0 - 5℃; for 1h; Product distribution / selectivity; Heating / reflux; | |
| In water; isopropyl alcohol at 0 - 5℃; for 1h; Product distribution / selectivity; Heating / reflux; |
What can I do for you?
Get Best Price
Specification
1. Introduction of Dasatinib monohydrate
Dasatinib monohydrate, with the IUPAC name of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate, is one kind of white crystalline powder, odorless, little bitter taste. And this chemical belongs to the Product Categories of Molecular Targeted Antineoplastic. In addition, it is a drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel.
2. Properties of Dasatinib monohydrate
Dasatinib monohydrate has the following properties:
Density: 1.408 g/cm3
Index of Refraction: 1.687
3. Use of Dasatinib monohydrate
Dasatinib (863127-77-9) is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma.